This pilot study found that BNA can identify patients with early PD using an advanced analysis of ERPs. These results need to be validated in a larger PD patient sample and assessed for people with premotor phase of PD. CLICK TO REVIEW
Background and Objectives: Short-chain fatty acids (SCFAs) are gut microbial metabolitesthat promote the disease process in a rodent model of Parkinson’s disease (PD), but fecallevels of SCFAs in PD patients are reduced. Simultaneous assessments of fecal and plasmaSCFA levels, and their inter-relationships with the PD disease process are scarce. We aimedto compare fecal and plasma
Exposure to systemic infections causes neurodegeneration in brain regions displaying amyloid pathology and high local microglia density. AD brains exhibit increased susceptibility to microbial PAMPs’ neurotoxicity, which accelerates neuronal death. Microglial modulation protects the brain from microbial TLR agonist PAMP-induced neurodegeneration. CLICK TO REVIEW
The human body is full of an extensive number of commensal microbes, consisting of bacteria, viruses, and fungi, collectively termed the human microbiome. The initial acquisition of microbiota occurs from both the external and maternal environments, and the vast majority of them colonize the gastrointestinal tract (GIT). These microbial communities play a central role in
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders Read More »
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and the fastest growing neurologic disease in the world, yet no disease-modifying therapy is available for this disabling condition. Multiple lines of evidence implicate the protein α-synuclein (α-Syn) in the pathogenesis of PD, and as such, there is intense interest in targeting α-Syn for potential disease modification. α-Syn
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson’s Disease Read More »
Braak’s hypothesis has been extremely influential over the last two decades. However, neuropathological and clinical evidence suggest that the model does not conform to all patients with Parkinson’s disease (PD). To resolve this controversy, a new model was recently proposed; in brain-first PD, the initial α-synuclein pathology arise inside the central nervous system, likely rostral to
Clinical and imaging evidence of brain-first and body-first Parkinson’s disease Read More »
Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed
Using MR, our findings provide further support for a causal relationship between dairy intake and higher PD risk, not biased by confounding or reverse causation. Further studies are needed to elucidate the underlying mechanisms. © 2022 International Parkinson and Movement Disorder Society CLICK TO REVIEW
Dairy Intake and Parkinson’s Disease: A Mendelian Randomization Study Read More »
Background: Over the last three decades, consumption of total and saturated fat has steadily declined in Western diets as a proportion of calories intake. At the same time, omega (ω)-6 fatty acid intake has risen at the expense of ω-3 fatty acids, resulting in an ω-6/ω-3 ratio of 20:1 or higher. Scope and approach: The
Current study provides a valuable and highly informative dataset of EV-associated sncRNAsfrom plasma of iRBD and PD patients. We identified miRNA signature features that could serve asminimally-invasive, blood-based surveillance biomarkers for distinguishing iRBD or PD from healthyindividuals with high sensitivity, specificity, and accuracy. CLICK TO REVIEW